Johnson & Johnson 2001 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 30, 2001. Johnson & Johnson is a global healthcare company employing approximately 101,800 people across 190 operating companies in virtually every country. The business is organized into three primary segments: Consumer (personal care, OTC drugs), Pharmaceutical (prescription drugs), and Medical Devices & Diagnostics. The company operates 148 manufacturing facilities worldwide totaling approximately 17 million square feet.
Key Financial Metrics
The provided text incorporates detailed financial statements by reference to the Annual Report to Shareowners and does not explicitly list total revenue, net income, or cash flow figures in the narrative. However, the following specific data points are disclosed:
- Research & Development Costs: $3,591 million for fiscal year 2001 (compared to $3,105 million in 2000 and $2,768 million in 1999). These costs are charged directly to income.
- Key Product Revenue Contribution: PROCRIT (epoetin alfa) accounted for 10.4% of total revenues in 2001.
- Customer Concentration: Sales to three major distributors (McKesson HBOC, Cardinal Distribution, and AmerisourceBergen Corp.) accounted for 10.4%, 10.3%, and 10.2% of total revenues, respectively, primarily within the Pharmaceutical segment.
- Market Capitalization: As of February 26, 2002, the aggregate market value of voting stock held by non-affiliates was approximately $181 billion.
- Stock Repurchases: As of March 15, 2002, the company repurchased 13,387,800 shares under a new $5 billion authorization at an average price of $60.83 per share.
- Valuation Reserves: Total reserves deducted from trade accounts receivable were $439 million at the end of 2001.
Material Changes and Operational Updates
- Acquisitions: In November 2001, the company completed the acquisition of Inverness Medical Technology, Inc.'s diabetes care products business.
- Merger Retroactivity: Financial schedules reflect retroactive effect for the merger with ALZA, completed on June 22, 2001.
- Leadership Transition: Chairman and CEO Ralph S. Larsen announced his retirement effective July 1, 2002.
- Management Changes: Several executive committee appointments were made in 2001, including Colleen A. Goggins as Worldwide Chairman of the Consumer & Personal Care Group and Christine A. Poon as Worldwide Chairman of the Pharmaceuticals Group.
Outlook, Risks, and Contingencies
Regulatory Environment: The company faces increasing stringency in government regulation regarding product safety, efficacy, and pricing, particularly from the FDA in the U.S. and harmonization efforts in the European Economic Community. Managed care is noted as a potent force influencing drug and device pricing and utilization.
Legal and Environmental: The company is involved in various legal proceedings, including Superfund claims for environmental remediation. Management believes these proceedings will not have a material adverse effect on financial position. The company maintains that its operations comply with environmental laws and that compliance costs are not expected to materially affect earnings.
Market Risks: International operations are subject to higher risks due to restrictive economic policies and political uncertainties in certain countries. Competition is described as strong across all product lines, requiring substantial investment in research and advertising.
Investor Verification Checklist
- Verify total revenue, net income, and operating margins for 2001 by consulting the "Selected Financial Data" and "Consolidated Statements of Earnings" referenced in the Annual Report to Shareowners (pages 25-31 and 32-48).
- Review the specific impact of the ALZA merger and the Inverness Medical Technology acquisition on segment performance.
- Assess the potential financial impact of the announced CEO succession plan following Ralph S. Larsen's retirement.
- Examine the "Legal Proceedings" note (Note 18) in the Annual Report for details on pending litigation and environmental liabilities.
- Confirm the status of the $5 billion stock repurchase program and its impact on share count and earnings per share.